Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health (NASDAQ:JAGX) will join the Russell Microcap Index effective June 28, 2021, enhancing its visibility and potentially broadening its institutional shareholder base. The inclusion in this index reflects Jaguar's market capitalization and growth attributes, which can attract investment managers looking for benchmarked stocks. This milestone aligns with the company's ongoing efforts to expand access to crofelemer, its plant-based product approved for treating noninfectious diarrhea in adults with HIV/AIDS.
Jaguar Health, Inc. (Nasdaq:JAGX) has adjourned its Annual Meeting of Stockholders originally scheduled for May 13, 2021, due to lack of quorum. The meeting will reconvene on July 9, 2021. Preliminary votes indicate over 76% support for key proposals, particularly Proposal 3, which seeks to increase the authorized shares of Common Stock from 150 million to 290 million. This increase aims to provide flexibility for future business needs and potential capital raises. The record date for eligible stockholders remains April 12, 2021.
Jaguar Health, Inc. (NASDAQ:JAGX) announced on June 4, 2021, the grant of stock options and restricted stock units (RSUs) to a new employee as inducement awards. Effective May 27, 2021, the company granted nonstatutory stock options for 225,000 shares with an exercise price of $1.68 per share, vesting over three years. Additionally, 112,500 RSUs were granted, vesting similarly over three years. These grants were approved by the Compensation Committee and are contingent on the employee's continued service.
Jaguar Health (NASDAQ:JAGX) announced a webcast interview with CEO Lisa Conte and Dragon SPAC founding sponsor Josh Mailman, scheduled for June 3, 2021, at 8:30 AM ET. The discussion will center on plans for Napo EU S.p.A., the company's Italian subsidiary, to seek conditional marketing authorization for crofelemer from the European Medicines Agency for treating short bowel syndrome (SBS), which leads to severe nutrient absorption issues. Jaguar aims to expand crofelemer access in Europe, capitalizing on its unique plant-based drug profile.
Jaguar Health and Dragon SPAC announced a private financing of approximately US$10.8 million to support the merger with Napo EU S.p.A. The funds will help pursue conditional marketing authorization for crofelemer, targeting short bowel syndrome, a market projected to reach US$4.6 billion by 2027. The deal involves Dragon SPAC issuing units, each including one ordinary share and a warrant. The financing is expected to close by Q2 2021, with the merger likely finalized within 30 days. This strategic shift aims to meet an unmet medical need in gastrointestinal health.
Jaguar Health and Dragon SPAC announced initial funding of $10.8 million for the Dragon SPAC private financing, aimed at facilitating a business combination with Napo EU, its Italian subsidiary. Napo EU plans to pursue conditional marketing authorization in the EU for crofelemer, targeting short bowel syndrome (SBS), a rare gastrointestinal condition. This orphan drug designation offers incentives like reduced fees and market exclusivity. The SBS market is projected to grow from $568 million in 2019 to $4.6 billion by 2027, with a CAGR of 26%.
Napo Pharmaceuticals, a subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), appointed Dr. Darlene Horton as Chief Medical Officer. Dr. Horton, a biopharmaceutical veteran, will enhance the company's phase 3 clinical trial for crofelemer, aimed at preventing cancer therapy-related diarrhea. Her extensive experience spans multiple therapeutic areas, having held senior roles at several biotech firms. The company is also pursuing conditional marketing authorization from the European Medicines Agency for crofelemer. This appointment is expected to drive further development of innovative gastrointestinal treatments.
Jaguar Health (NASDAQ:JAGX) announced significant findings related to cancer-related diarrhea (CRD) through its subsidiary, Napo Pharmaceuticals. Three abstracts have been accepted for presentation at the ASCO Annual Meeting from June 4-8, 2021. Key findings show that patients with CRD are 40% more likely to discontinue chemotherapy, leading to increased healthcare resource utilization and costs, with those affected incurring nearly 2.9 times higher costs than non-CRD patients. The need for effective CRD management is emphasized to enhance treatment adherence.
Jaguar Health (NASDAQ:JAGX) has launched a new Instagram page to foster community engagement and awareness. The platform will host jaguar-themed contests and provide educational content related to plant-based medicines and environmental conservation. A caption contest will run until May 26, with submissions judged by a panel including the company's CEO. Additionally, the page will promote activities in recognition of HIV Long-Term Survivors Awareness Day on June 5. Jaguar is focused on developing plant-based drugs for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) has announced progress on its Canalevia drug candidate, the first FDA-approved plant-based medicine for treating chemotherapy-induced diarrhea (CID) in dogs. With over 50,000 dogs experiencing CID annually, Canalevia aims to provide relief for these pets during cancer treatment. The company plans to submit applications for conditional approval by Q4 2021. Additionally, Jaguar is working on approval for exercise-induced diarrhea (EID) in working dogs. Canalevia is positioned to enhance the quality of life for dogs undergoing chemotherapy, benefiting pet owners and veterinary teams alike.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
